Published On: 8/24/2020
TARGET-NASH Expands to Europe, Enrolls First Participant
Target RWE, an innovative health evidence solutions company generating real-world evidence (RWE) and delivering regulatory-grade data to partners to advance clinical, medical, and commercial outcomes, has announced its nonalcoholic steatohepatitis (NASH) longitudinal study, TARGET-NASH, has enrolled its first European patient.
“Our TARGET-NASH study continues to grow and lead real-world evidence generation in NASH. TARGET-NASH enrolling its first European patient is an important step forward and will provide important perspectives for our key stakeholders on this growing health concern,” said Target RWE CEO Neal Bibeau.
Launched in 2016, TARGET-NASH is an observational study of more than 5,000 participants diagnosed with nonalcoholic fatty liver disease (NAFLD). Target RWE’s network of sites includes both community and academic centers and enrolls adult and pediatric participants across the spectrum of this liver disease. Once enrolled, three years of retrospective data and five years of prospective data is collected from TARGET-NASH participants, including Patient-Reported Outcomes (PRO) and biorepository samples.
The TARGET-NASH dataset is critical to providing a baseline and measuring the impact of current practice guidelines, management, and new therapies utilized for patients with medical co-morbidities, hepatic, cardiovascular, and/or other endocrine-associated outcomes.
TARGET-NASH was the first study established by Target RWE when the company was created in 2015. Target RWE has added seven additional studies to its portfolio since then including: hepatocellular carcinoma (HCC), inflammatory bowel disease (IBD), primary biliary cholangitis (PBC), immune-mediated inflammatory skin conditions (DERM), chronic hepatitis B (HBV), asthma, and COVID-19.
About Target RWE
As the industry's best-in-class, complete real world evidence (RWE) solution, Target RWE is a distinctly collaborative enterprise that unifies real world data (RWD) sets and advanced RWE analytics in an integrated community, shifting the paradigm in healthcare for how decisions are made to improve lives.
Target RWE sources unique, connected data sets across multiple therapeutic areas representing granular data from diverse patients in academic and community settings. Our rigorous, interactive, and advanced RWE analytics extract deep insights from RWD to answer important questions in healthcare. Target RWE brings together the brightest minds in healthcare through an unmatched community of key opinion leaders, patients, and healthcare stakeholders in a collaborative and dynamic model. www.targetrwe.com
Contact:
Kayla Slake
Marketing Manager
984.234.0268 ext 205
More News
-
09/21/2023
New Eosinophilic Gastrointestinal Disorders (EGIDs) Real World Registry Surpasses 1,000 Patient Milestone -
08/23/2023
Target RWE's Cutting-Edge Analytical Solutions Launched to Propel Real-World Evidence Generation -
08/22/2023
Target RWE Strengthens Industry Leadership Position with Novel Real World Evidence Approaches Presented at ICPE 2023 -
06/21/2023
World-Leading Real World Data Registry, TARGET-NASH, Surpasses 7,000+ Enrolled Patients and 500,000+ Months of Patient Follow-Up -
06/02/2023
Event Recap Blog: TARGET-NASH Analysis Presented at ISPOR 2023 and Target RWE Leaders Present at PMSA 2023